Investigational drug · Phase 2
Onvansertib
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
13
Any phase or sponsor naming "Onvansertib"
First trial start
2023
Mar 17, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Onvansertib", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Metastatic Colorectal Cancer
- CRC
- KRAS/NRAS Mutation
- Colorectal Cancer
Approved drugs for the same conditions: Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Onvansertib" as an intervention, largest first.
- Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationPivotal-lookingActive, not recruiting
Cardiff OncologyIndustry
NCT06106308 · 110 participants · Start Feb 27, 2024 · Primary completion Apr 16, 2027
Drug: Onvansertib; FOLFIRI and 2 more · For: Metastatic Colorectal Cancer; CRC; KRAS/NRAS Mutation
Sites: Phoenix, Arizona; Tucson, Arizona; Jonesboro, Arkansas · 41 sites in all
OHSU Knight Cancer InstituteAcademic, hospital or other
NCT04005690 · 90 participants (planned) · Start Aug 1, 2019 · Primary completion Jun 1, 2027
Drug: Cobimetinib; Olaparib and 4 more · For: Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8 and 5 more
Sites: Portland, Oregon
Cardiff OncologyIndustry
NCT03414034 · 72 participants · Start Aug 14, 2018 · Primary completion Oct 16, 2023
Drug: Onvansertib; Abiraterone and 1 more · For: Metastatic Castration-Resistant Prostate Cancer
Sites: Boston, Massachusetts · 3 sites in all
Cardiff OncologyIndustry
NCT03303339 · 72 participants · Start Nov 17, 2017 · Primary completion Nov 17, 2021
Drug: Onvansertib; Cytarabine and 1 more · For: Acute Myeloid Leukemia
Sites: Los Angeles, California; New Haven, Connecticut; Westwood, Kansas · 9 sites in all
Cardiff OncologyIndustry
NCT03829410 · 68 participants · Start Jun 24, 2019 · Primary completion Jan 29, 2024
Drug: Onvansertib; Bevacizumab and 1 more · For: Metastatic Colorectal Cancer; KRAS Gene Mutation
Sites: Phoenix, Arizona; Little Rock, Arkansas; Los Angeles, California · 7 sites in all
- Onvansertib + Paclitaxel In TNBCActive, not recruiting
Antonio Giordano, MDAcademic, hospital or other
NCT05383196 · 50 participants (planned) · Start Sep 30, 2022 · Primary completion Dec 15, 2026
Drug: Onvansertib; Paclitaxel · For: Breast Cancer; Invasive Breast Cancer; Unresectable Breast Carcinoma and 7 more
Sites: Boston, Massachusetts · 3 sites in all
Cardiff OncologyIndustry
NCT04752696 · 41 participants · Start May 25, 2021 · Primary completion Dec 24, 2024
Drug: Onvansertib; Nanoliposomal irinotecan and 2 more · For: Pancreatic Ductal Adenocarcinoma
Sites: Phoenix, Arizona; Jacksonville, Florida; Westwood, Kansas · 6 sites in all
University of Maryland, BaltimoreAcademic, hospital or other
NCT05450965 · 37 participants (planned) · Start Jul 19, 2022 · Primary completion Aug 31, 2027
Drug: Onvansertib · For: Small-cell Lung Cancer; Small Cell Lung Carcinoma
Sites: Baltimore, Maryland; Pittsburgh, Pennsylvania
Mayo ClinicAcademic, hospital or other
NCT05549661 · 25 participants (planned) · Start Apr 4, 2023 · Primary completion Jun 1, 2027
Drug: Onvansertib · For: Recurrent Chronic Myelomonocytic Leukemia; Refractory Chronic Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified and 3 more
Sites: Rochester, Minnesota
Cardiff OncologyIndustry
NCT05593328 · 23 participants · Start Mar 17, 2023 · Primary completion Dec 9, 2024
Drug: Onvansertib; FOLFIRI and 1 more · For: Colorectal Cancer; Metastatic Colorectal Cancer
Sites: Phoenix, Arizona; Little Rock, Arkansas; Anaheim, California · 27 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Onvansertib-mediated PLK1 inhibition impairs spermatogenesis in the murine testis.
Qi XX, Feng X, Zhu WR, et al. · Asian J Androl 2026
- PLK1 inhibition by onvansertib enhances paclitaxel efficacy and overcomes resistance in HR+/HER2- breast cancer refractory to endocrine therapy and CDK4/6 inhibitors.
Sreekumar S, Gonzalez ME, Klein D, et al. · Mol Cancer Ther 2026
- Inhibition of PLK1 helps to restrict c-Met-induced growth and therapeutic resistance of renal cancer cells.
Pal S, Rawat L, Prakash CM, et al. · Mol Cancer Ther 2026
- Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers.
Gustafson DL, Early KA, Morales MA, et al. · Vet Comp Oncol 2026
- All screens lead to polo-like kinase 1: A central node in cancer therapeutics and resistance.
Al-Souhibani N, Menyhart O, Dufies M, et al. · Pharmacol Res 2026
- Identification of Polo-like kinase-1 (PLK-1) inhibitors from Centella asiatica (Gotu Kola) using UHPLC and in-silico approaches.
Ali K, Khan MA, Ansari WA, et al. · Nat Prod Res 2026
Also in development for Metastatic Colorectal Cancer
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
- CyclophosphamidPhase 33 trials
Alentis Therapeutics AG · Glomerulonephritis Rapidly Progressive, Diffuse Large B-Cell Lymphoma (DLBCL), Metastatic Colorectal Cancer
- CTX-009Phase 32 trials
Compass Therapeutics · Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer
- Precemtabart tocentecanPrecem-TcT, M9140Phase 32 trials
EMD Serono Research & Development Institute, Inc. · Metastatic Colorectal Cancer, Solid Tumors, Gastric Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.